Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Kelly

Internal Medicine Phoenix, AZ Medical Doctor

NPI 1528068178 CMS profile 23240

3815 E Bell Rd, Suite 4100, Phoenix, AZ 85032

Open in the dashboard

General payments

$3,621

136 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$115,881 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Richard Kelly of Phoenix, AZ is reported in the CMS Open Payments database as having received $3,621 across 136 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $115,881 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $60 3
2024 General $45 2
2023 General $404 15
2022 General $484 21
2021 General $1,365 40
2020 General $309 14
2019 General $954 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Kelly
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Richard Kelly were reported at $60. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Richard Kelly Internal Medicine median Middle half National median
2019 $954 $159 $48–$570 $163
2020 $309 $119 $33–$402 $114
2021 $1,365 $135 $37–$521 $132
2022 $484 $141 $42–$496 $149
2023 $404 $149 $45–$519 $160
2024 $45 $154 $47–$537 $164
2025 $60 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $873 7 payments
  2. Sanofi-Aventis U.S. LLC $390 8 payments
  3. AbbVie, Inc. $353 24 payments
  4. Astellas Pharma US Inc $250 11 payments
  5. GlaxoSmithKline, LLC. $237 9 payments
  6. Abbott Laboratories $197 10 payments
  7. Pfizer Inc. $170 17 payments
  8. Amgen Inc. $164 9 payments
  9. Lilly USA, LLC $158 9 payments
  10. Novo Nordisk Inc $149 3 payments
  11. Other $680 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,723 133 payments
  2. Consulting Fee $768 1 payment
  3. Education $131 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $840 6 payments
  2. TOUJEO $255 5 payments
  3. MYRBETRIQ $229 10 payments
  4. TRELEGY ELLIPTA $169 5 payments
  5. Ozempic $138 2 payments
  6. SOLIQUA 100/33 $135 3 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $129 1 payment
  8. Xhance $123 1 payment
  9. EVENITY $121 7 payments
  10. Prolia $121 7 payments
  11. Other $1,804 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

825

Median for Internal Medicine: 777

Drug cost

$9,830

Median for Internal Medicine: $73,373

Branded share of claims

7.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Omeprazole Generic 38 $856
Atorvastatin Calcium Generic 64 $828
Levothyroxine Sodium Generic 59 $625
Fluticasone Propionate Generic 26 $596
Gabapentin Generic 22 $519
Metformin Hcl Generic 45 $497
Lisinopril Generic 54 $412
Famotidine Generic 12 $411
Hydroxyzine Hcl Generic 15 $386
Pioglitazone Hcl Generic 12 $347

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$40,934

Of which drugs: $1,834

Medicare patients

246

Average age 76

Services billed

922

156 women, 90 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Chronic kidney disease 32%
Ischemic heart disease 31%
Diabetes 30%
Depression 27%
Osteoporosis 26%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 15 15 $1,227

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

136 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record